MX2020004403A - Composiciones farmaceuticas que comprenden safinamida. - Google Patents
Composiciones farmaceuticas que comprenden safinamida.Info
- Publication number
- MX2020004403A MX2020004403A MX2020004403A MX2020004403A MX2020004403A MX 2020004403 A MX2020004403 A MX 2020004403A MX 2020004403 A MX2020004403 A MX 2020004403A MX 2020004403 A MX2020004403 A MX 2020004403A MX 2020004403 A MX2020004403 A MX 2020004403A
- Authority
- MX
- Mexico
- Prior art keywords
- safinamide
- pharmaceutical compositions
- particles
- taste
- prepare
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Zoology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La presente invención se relaciona con composiciones farmacéuticas que comprenden la safinamida y, más particularmente, con partículas que enmascaran el sabor, que comprenden el ingrediente activo tal o las sales farmacéuticamente aceptables del mismo, formas de dosificación oral que incluyen las partículas tales y un proceso para prepararlas.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT201700124545 | 2017-11-02 | ||
PCT/EP2018/079635 WO2019086408A1 (en) | 2017-11-02 | 2018-10-30 | Pharmaceutical compositions comprising safinamide |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2020004403A true MX2020004403A (es) | 2020-08-06 |
Family
ID=61527030
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020004403A MX2020004403A (es) | 2017-11-02 | 2018-10-30 | Composiciones farmaceuticas que comprenden safinamida. |
Country Status (13)
Country | Link |
---|---|
US (1) | US11103457B2 (es) |
EP (1) | EP3703665A1 (es) |
JP (1) | JP2021508316A (es) |
CN (1) | CN111432806A (es) |
AU (1) | AU2018357886B2 (es) |
BR (1) | BR112020008653A2 (es) |
CA (1) | CA3080975A1 (es) |
CO (1) | CO2020006552A2 (es) |
EA (1) | EA202091127A1 (es) |
IL (1) | IL274144A (es) |
MX (1) | MX2020004403A (es) |
WO (1) | WO2019086408A1 (es) |
ZA (1) | ZA202003079B (es) |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030096791A1 (en) * | 2001-05-31 | 2003-05-22 | Cima Labs Inc. | Taste masking of highly water-soluble drugs |
AR044007A1 (es) | 2003-04-11 | 2005-08-24 | Newron Pharmaceuticals Inc | Metodos para el tratamiento de la enfermedad de parkinson |
WO2011098456A1 (en) | 2010-02-09 | 2011-08-18 | Merck Serono S.A. | Safinamide in the treatment of dyskinesia |
JP5680898B2 (ja) * | 2010-08-10 | 2015-03-04 | 京都薬品工業株式会社 | 苦味を抑制した速崩壊錠 |
FR2971422B1 (fr) * | 2011-02-11 | 2016-05-20 | Debregeas Et Associes Pharma | Granules d'acide gamma-hydroxybutyrique |
EP2594266B1 (en) | 2011-11-17 | 2014-07-30 | Zambon S.p.A. | Pharmaceutical solid compositions containing ibuprofen salts |
CA2900597C (en) * | 2013-02-14 | 2021-11-02 | Sanofi | Chewable composition for oral administration and process for preparing thereof |
AU2014228861B2 (en) * | 2013-03-15 | 2018-05-24 | Aprecia Pharmaceuticals LLC | Rapidly dispersible dosage form of topiramate |
ITMI20130874A1 (it) * | 2013-05-29 | 2014-11-30 | Zambon Spa | Compresse deglutibili di n-acetilcisteina |
CA2955972A1 (en) * | 2014-07-22 | 2016-01-28 | Bioventures, Llc. | Compositions and methods for selectively depleting senescent cells |
CN104546747A (zh) | 2014-11-20 | 2015-04-29 | 美吉斯制药(厦门)有限公司 | 一种含有甲磺酸沙芬酰胺的药物组合物及其制备方法 |
ITUA20163981A1 (it) * | 2016-05-31 | 2017-12-01 | Zambon Spa | Composizioni farmaceutiche comprendenti safinamide |
CN106667940A (zh) | 2017-02-22 | 2017-05-17 | 佛山市弘泰药物研发有限公司 | 一种沙芬酰胺分散片及其制备方法 |
CN106983730A (zh) * | 2017-02-22 | 2017-07-28 | 佛山市弘泰药物研发有限公司 | 一种沙芬酰胺胃溶型微丸片及其制备方法 |
-
2018
- 2018-10-30 US US16/760,977 patent/US11103457B2/en active Active
- 2018-10-30 EA EA202091127A patent/EA202091127A1/ru unknown
- 2018-10-30 JP JP2020524227A patent/JP2021508316A/ja active Pending
- 2018-10-30 EP EP18803878.0A patent/EP3703665A1/en active Pending
- 2018-10-30 MX MX2020004403A patent/MX2020004403A/es unknown
- 2018-10-30 WO PCT/EP2018/079635 patent/WO2019086408A1/en unknown
- 2018-10-30 CA CA3080975A patent/CA3080975A1/en active Pending
- 2018-10-30 BR BR112020008653-3A patent/BR112020008653A2/pt unknown
- 2018-10-30 AU AU2018357886A patent/AU2018357886B2/en active Active
- 2018-10-30 CN CN201880077663.XA patent/CN111432806A/zh active Pending
-
2020
- 2020-04-22 IL IL274144A patent/IL274144A/en unknown
- 2020-05-25 ZA ZA2020/03079A patent/ZA202003079B/en unknown
- 2020-05-28 CO CONC2020/0006552A patent/CO2020006552A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
CN111432806A (zh) | 2020-07-17 |
AU2018357886A1 (en) | 2020-05-07 |
CO2020006552A2 (es) | 2020-08-21 |
CA3080975A1 (en) | 2019-05-09 |
ZA202003079B (en) | 2023-02-22 |
BR112020008653A2 (pt) | 2020-10-27 |
WO2019086408A1 (en) | 2019-05-09 |
AU2018357886B2 (en) | 2024-04-18 |
US11103457B2 (en) | 2021-08-31 |
IL274144A (en) | 2020-06-30 |
EP3703665A1 (en) | 2020-09-09 |
JP2021508316A (ja) | 2021-03-04 |
EA202091127A1 (ru) | 2020-09-22 |
US20200315969A1 (en) | 2020-10-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY35933A (es) | Composiciones farmacéuticas que comprenden azd9291 | |
CO2018004776A2 (es) | Composiciones terapéuticas para el tratamiento del virus de inmunodeficiencia humana | |
CL2020000747A1 (es) | Formulaciones de niraparib. | |
EA201792592A1 (ru) | Фармацевтические препараты, содержащие тенофовир и эмтрицитабин | |
EA201990424A1 (ru) | Спиролактамовые модуляторы nmda-рецептора и их применение | |
EA201990428A1 (ru) | Спиролактамовые модуляторы nmda-рецептора и их применение | |
CY1124041T1 (el) | Συνθεσεις που περιλαμβανουν κυκλοσπορινη | |
CO2016003340A2 (es) | Formulaciones farmacéuticas, procesos para la preparación y métodos de uso | |
SG10201902203VA (en) | Eutectic formulations of cyclobenzaprine hydrochloride | |
CL2017001840A1 (es) | Formulaciones farmacéuticas que comprenden cangrelor de alta pureza y métodos para preparar y usar las mismas. | |
BR112017004948A2 (pt) | formulação farmacêutica. | |
MX2020012989A (es) | Agente terapeutico para la fibrosis. | |
CO2018014217A2 (es) | Composiciones farmacéuticas que comprenden safinamida | |
BR112017023425A2 (pt) | combinações terapêuticas de terapias antivirais e anti-inflamatórias | |
PH12018500817A1 (en) | Pharmaceutical composition comprising metformin and lobeglitazone | |
CL2018003338A1 (es) | Formulaciones inyectables fisiológicamente balanceadas de fosnetupitant. | |
CL2017002229A1 (es) | Inhibidores de bace1. | |
BR112019001024A2 (pt) | combinação de um inibidor de bcl-2 e um inibidor de mcl-1, seus usos e composições farmacêuticas | |
MX2020004403A (es) | Composiciones farmaceuticas que comprenden safinamida. | |
TR201721700A2 (tr) | Saksagli̇pti̇ni̇n ağizda dağilan formülasyonlari | |
MX2017008879A (es) | Composicion farmaceutica para el tratamiento de la micosis. | |
CL2020000251A1 (es) | Derivado de adamantilmetilamina y uso del mismo como producto farmacéutico. | |
EA201691422A1 (ru) | Перорально распадающиеся таблетированные составы мемантина | |
EA201891848A1 (ru) | Фармацевтическая композиция для применения в лечении фиброза | |
PH12016502527B1 (en) | Stabilized desmopressin |